+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Psoriatic Arthritis

  • ID: 4775382
  • Report
  • September 2020
  • Region: Global
  • 65 pages
  • Datamonitor Healthcare

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AbbVie
  • Amgen
  • Celgene
  • Johnson & Johnson
  • MORE
This Market Spotlight report covers the psoriatic arthritis market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, patent information, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways
  • The approved drugs in the psoriatic arthritis space focus on a wide variety of targets. The majority of approved drugs are administered via the subcutaneous route, with the remainder being intravenous, intramuscular, oral, and topical formulations.
  • The majority of industry-sponsored drugs in active clinical development for psoriatic arthritis are in Phase III, with only one drug in the NDA/BLA stage.
  • Therapies in development for psoriatic arthritis focus on targets such as TNF-alpha, IL-23, JAK/STAT, IL-17, selectins, and tyrosine kinase 2. These drugs are administered via the oral, subcutaneous, and intravenous routes.
  • High-impact upcoming events for drugs in the psoriatic arthritis space comprise topline Phase III trial results for bimekizumab, topline Phase II trial results for BMS-986165, and an estimated PDUFA date as well as expected CHMP supplemental filing results for Tremfya.
  • The overall likelihood of approval of a Phase I psoriasis asset is 13%, and the average probability a drug advances from Phase III is 75%. Drugs, on average, take 7.7 years from Phase I to approval, compared to 9.0 years in the overall autoimmune/immunology space.
  • The distribution of clinical trials across Phase I–IV indicates that the majority of trials for psoriatic arthritis have been in the late phases of development, with 79% of trials in Phase III–IV, and only 21% in Phase I–II.
  • The US leads in terms of the number of psoriatic arthritis clinical trials globally, while Germany leads the major European markets.
  • Clinical trial activity in the psoriatic arthritis space is dominated by completed trials. AbbVie has the highest number of completed clinical trials for psoriatic arthritis, with 31 trials.
  • AbbVie leads industry sponsors with the highest overall number of clinical trials for psoriatic arthritis, followed by Bristol Myers Squibb.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie
  • Amgen
  • Celgene
  • Johnson & Johnson
  • MORE
Overview

Key Takeaways

Disease Background
  • Disease definition
  • Patient subtypes
  • Symptoms
  • Risk factors
  • Diagnosis
Treatment
  • Topical treatments
NSAIDs
  • Corticosteroids
  • Light therapy
DMARDs
  • Biologics
Epidemiology
  • Prevalence
  • Prevalence among patients with psoriasis
Marketed Drugs

Pipeline Drugs

Recent Events and Analyst Opinion
  • Rinvoq for Psoriatic Arthritis (February 5, 2020)
  • Taltz for Psoriatic Arthritis (November 12, 2019)
  • Tremfya for Psoriatic Arthritis (November 11, 2019)
  • Cosentyx for Psoriatic Arthritis (November 1, 2019)
  • Rinvoq for Psoriatic Arthritis (October 31, 2019)
  • Inflectra for Psoriatic Arthritis (September 19, 2019)
  • Otezla for Psoriatic Arthritis (August 26, 2019)
  • Ilumya for Psoriatic Arthritis (June 27, 2019)
  • Ilumya for Psoriatic Arthritis (June 14, 2019)
  • Tremfya for Psoriatic Arthritis (June 14, 2019)
  • Cosentyx for Psoriatic Arthritis (June 12, 2019)
  • SensoReady Injector Pen for Psoriatic Arthritis (April 9, 2019)
Key Upcoming Events

Key Regulatory Events
  • Extra Indications Approved For Celltrion’s Remsima SC
  • FDA Approves Mylan’s Humira Biosimilar
  • J&J Bids To Strengthen Simponi’s Pediatric Labeling
  • Mylan And Lupin Get EU Etanercept Nod
  • Amgen To Launch Newly Approved Remicade Biosimilar Before July
  • Janssen Submits Tremfya For First-In-Class Active Psoriatic Arthritis Approval
Probability of Success

Licensing and Asset Acquisition Deals
  • Bio-Thera Out-Licenses Golimumab To Russia And CIS
  • Deals Shaping The Medical Industry, January 2020
  • Amgen’s $13.4bn Otezla Buy Helps Bristol/Celgene Merger Close By Year-End
Revenue Opportunity

Clinical Trial Landscape
  • Sponsors by status
  • Sponsors by phase
  • Recent events
Bibliography
  • Prescription information
Appendix

List of Figures
  • Figure 1: Overview of pipeline drugs for psoriatic arthritis in the US
  • Figure 2: Pipeline drugs for psoriatic arthritis, by company
  • Figure 3: Pipeline drugs for psoriatic arthritis, by drug type
  • Figure 4: Pipeline drugs for psoriatic arthritis, by classification
  • Figure 5: Rinvoq for Psoriatic Arthritis (February 5, 2020): Phase III - SELECT-PsA-1
  • Figure 6: Tremfya for Psoriatic Arthritis (November 11, 2019): Phase III - Discover-1, Phase III - Discover-2
  • Figure 7: Cosentyx for Psoriatic Arthritis (November 1, 2019): Phase IIIb - EXCEED 1 (vs. Adalimumab)
  • Figure 8: Rinvoq for Psoriatic Arthritis (October 31, 2019): Phase III - SELECT-PsA-2
  • Figure 9: Ilumya for Psoriatic Arthritis (June 14, 2019): Phase IIb - CLR_16_23
  • Figure 10: Tremfya for Psoriatic Arthritis (June 14, 2019): Phase III - Discover-1, Phase III - Discover-2
  • Figure 11: Cosentyx for Psoriatic Arthritis (June 12, 2019): Phase IIIb - MAXIMISE
  • Figure 12: Key upcoming events in psoriatic arthritis
  • Figure 13: Probability of success in the psoriatic arthritis pipeline
  • Figure 14: Clinical trials in psoriatic arthritis
  • Figure 15: Top 10 drugs for clinical trials in psoriatic arthritis
  • Figure 16: Top 10 companies for clinical trials in psoriatic arthritis
  • Figure 17: Trial locations in psoriatic arthritis
  • Figure 18: Psoriatic arthritis trials status
  • Figure 19: Psoriatic arthritis trials sponsors, by phase
List of Tables
  • Table 1: Marketed drugs for psoriatic arthritis
  • Table 2: Pipeline drugs for psoriatic arthritis in the US
  • Table 3: Rinvoq for Psoriatic Arthritis (February 5, 2020)
  • Table 4: Taltz for Psoriatic Arthritis (November 12, 2019)
  • Table 5: Tremfya for Psoriatic Arthritis (November 11, 2019)
  • Table 6: Cosentyx for Psoriatic Arthritis (November 1, 2019)
  • Table 7: Rinvoq for Psoriatic Arthritis (October 31, 2019)
  • Table 8: Inflectra for Psoriatic Arthritis (September 19, 2019)
  • Table 9: Otezla for Psoriatic Arthritis (August 26, 2019)
  • Table 10: Ilumya for Psoriatic Arthritis (June 27, 2019)
  • Table 11: Ilumya for Psoriatic Arthritis (June 14, 2019)
  • Table 12: Tremfya for Psoriatic Arthritis (June 14, 2019)
  • Table 13: Cosentyx for Psoriatic Arthritis (June 12, 2019)
  • Table 14: SensoReady Injector Pen for Psoriatic Arthritis (April 9, 2019)
  • Table 15: Historical global sales, by drug ($m), 2015–19
  • Table 16: Forecasted global sales, by drug ($m), 2020–24
Note: Product cover images may vary from those shown
  • AbbVie
  • Amgen
  • Celgene
  • Johnson & Johnson
Note: Product cover images may vary from those shown
Adroll
adroll